Glenmark Pharma arm gets US FDA final nod for asthma inhaler
This story was originally published at 09:09 IST on 4 March 2026
Register to read our real-time news.Informist, Wednesday, Mar. 4, 2026
MUMBAI – Glenmark Pharmaceuticals Ltd.'s subsidiary Glenmark Specialty SA has got final approval from the US Food and Drug Administration for fluticasone propionate inhalation aerosol. It is an inhaler used to prevent asthma symptoms.
Glenmark Pharmaceuticals Inc., another subsidiary of Glenmark Pharma, will distribute the inhaler starting this month. The approved drug is equivalent to the FloVent brand inhaler of GlaxoSmithKline Intellectual Property Ltd. FloVent had sales of around $520 million in the US for the 12 months ended January.
For the December quarter, Glenmark Pharma had reported a consolidated net profit of INR 4.03 billion on a revenue of INR 39.01 billion. Monday, its shares had closed at INR 2,123.30 on the National Stock Exchange, down 0.6%. The stock markets were shut Tuesday for Holi. End
Reported by Anshul Choudhary
Edited by Rajeev Pai
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
